$10.34
0.111.12%
Last update: Nov 12, 11:58 AM
MiNK Therapeutics Inc
INKTNASDAQ
MiNK Therapeutics fell 25.3% from $13.68 to $10.22, behind the S&P 500's +11.2%. Its worst day was Mar 11 (−17.2%), and its low came Mar 24 at $8.56.
Nov 12, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.65 beat the $-0.86 estimate on $0.00 revenue.
−3.6% · S&P 500 0.0%
MiNK Therapeutics shares rose 11.8%, while the S&P 500 rose 0.1%.
Story events cover the past 12 months · Times ET
+11.8% · S&P 500 +0.1%
MiNK Therapeutics (NASDAQ:INKT) a clinical-stage biopharmaceutical company advancing invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases, today announced a strategic collaboration
+30.8%, the year's best day, on 16M shares, the year's heaviest volume · S&P 500 −0.2%
EPS of $-0.56 beat the $-0.68 estimate on $0.00 revenue.
+0.1% · S&P 500 +2.9%
MiNK Therapeutics closed at its highest level of the year, 3.9% above where the year started.
+0.6% · S&P 500 +1.2%
EPS of $-0.57 beat the $-0.77 estimate on $0.00 revenue.
+2.0% · S&P 500 −1.2%
First patient dosed marks rapid transition from trial activation to active treatment in patients with acute lung injury from all cause pneumonia meeting Global ARDS criteriaLandmark advances a first-in-class immune
+19.8% · S&P 500 +0.6%
EPS of $-0.62 missed the $-0.60 estimate on $0.00 revenue.
−3.2% · S&P 500 +0.7%
EPS of $-0.50 beat the $-0.53 estimate on $200,000.00 revenue (est. $150,000.00).
+2.1% · S&P 500 +1.3%
Where it ended: a close of $10.22 on Nov 11, 2026.
Nothing in the past 12 months.
All INKT dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for INKT and SPY from Benzinga historical bars. Not investment advice.
